Literature DB >> 8408185

In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.

A H Jäger1, U Bogdahn, R Apfel, B Pfeufer, A Dekant.   

Abstract

Drug interference of ifosfamide and sodium 2-mercaptoethanesulphonate (MESNA) was studied in three malignant glioma cell cultures (HTZ-17, HTZ-209B, and HTZ-243) by a recently developed in vitro method for evaluation of multimodal treatment interactions. Glioma cell cultures were treated in monolayer 96-well tissue-culture plates for 2 h each, with 4-hydroperoxyifosfamide and MESNA combined in both sequences, or alone. Concentrations ranged from 0.01 microM to 50 microM in single-modality exposures, and from 0.01 microM to 10 microM in combination exposures. After five population doubling times, DNA synthesis was determined by a standard [3H]Tdr-incorporation liquid-scintillation-counting protocol. Data points were evaluated for mono- and combined treatment dose effects (adapted with a probit function), and a model-free three-dimensional response surface was created that was compared to the theoretical additive, anticipated response surface. Local additivity was analysed for any ratio of combined treatment. No tumour effects were seen with MESNA in single-drug exposure, whereas ifosfamide resulted in more than 90% inhibition of tumour DNA synthesis. In combination experiments, MESNA could be confirmed to be inert: the anticipated theoretical combination response surfaces formed a three-dimensional extension of the single-drug ifosfamide dose/response curves--the experimental combination response surfaces displayed an identical appearance (P < or = 0.05). In conclusion, these results indicate no drug interference of MESNA and ifosfamide in malignant glioma cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408185     DOI: 10.1007/bf01195343

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  THE METHOD OF PROBITS--A CORRECTION.

Authors:  C I Bliss
Journal:  Science       Date:  1934-05-04       Impact factor: 47.728

2.  Ifosfamide/mesa and encephalopathy.

Authors:  B M Cantwell; A L Harris
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

3.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

4.  Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro.

Authors:  H Blomgren; M Hallström; H Hillgren
Journal:  Methods Find Exp Clin Pharmacol       Date:  1990-12

5.  Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.

Authors:  T Wagner; M Zink; G Schwieder
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

Authors:  T C Chou; P Talalay
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.486

7.  Chemosensitivity of malignant human brain tumors. Preliminary results.

Authors:  U Bogdahn
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours.

Authors:  U Bogdahn; D Drenkard; M Lutz; R Apfel; C Behl
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.

Authors:  C B Pratt; E C Douglass; E Etcubanas; M P Goren; A A Green; F A Hayes; M E Horowitz; W H Meyer; E I Thompson; J A Wilimas
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.